These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8661976)

  • 1. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
    Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R; Sigaud A; Azria M; Herrmann FR
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
    Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
    Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
    Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
    J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N; Bone H; Gilligan JP; Krause DS
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I; Saastamoinen J; Alhava EM
    Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
    Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.